X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2913) 2913
Publication (189) 189
Book Review (134) 134
Magazine Article (5) 5
Conference Proceeding (3) 3
Book Chapter (1) 1
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2794) 2794
atorvastatin calcium (2296) 2296
heptanoic acids - pharmacology (2004) 2004
humans (1837) 1837
pyrroles - pharmacology (1696) 1696
male (1686) 1686
animals (1256) 1256
atorvastatin (1113) 1113
female (1041) 1041
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (982) 982
pharmacology & pharmacy (950) 950
heptanoic acids - therapeutic use (927) 927
pyrroles - therapeutic use (880) 880
statins (858) 858
middle aged (812) 812
rats (639) 639
aged (527) 527
adult (502) 502
cholesterol (490) 490
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (487) 487
simvastatin (472) 472
heptanoic acids - administration & dosage (469) 469
anticholesteremic agents - pharmacology (453) 453
pyrroles - administration & dosage (447) 447
dose-response relationship, drug (373) 373
cardiac & cardiovascular systems (366) 366
mice (355) 355
atherosclerosis (350) 350
pravastatin (321) 321
peripheral vascular disease (290) 290
antilipemic agents (287) 287
anticholesteremic agents - therapeutic use (286) 286
hypercholesterolemia - drug therapy (277) 277
cholesterol - blood (263) 263
inflammation (261) 261
cells, cultured (260) 260
cholesterol, ldl - blood (260) 260
hypercholesterolemia (259) 259
treatment outcome (252) 252
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (244) 244
expression (242) 242
simvastatin - pharmacology (236) 236
abridged index medicus (230) 230
time factors (213) 213
heptanoic acids - adverse effects (212) 212
rats, sprague-dawley (212) 212
analysis (211) 211
disease models, animal (211) 211
lipids (209) 209
coa reductase inhibitors (204) 204
pyrroles - adverse effects (203) 203
rats, wistar (203) 203
biochemistry & molecular biology (199) 199
heptanoic acids - pharmacokinetics (199) 199
statin (197) 197
drug interactions (194) 194
oxidative stress (194) 194
drug therapy, combination (188) 188
double-blind method (183) 183
pyrroles - pharmacokinetics (182) 182
triglycerides - blood (181) 181
lipids - blood (174) 174
disease (172) 172
hmg-coa reductase (170) 170
research (163) 163
endothelium, vascular - drug effects (160) 160
simvastatin - therapeutic use (159) 159
nitric-oxide synthase (156) 156
in-vitro (154) 154
drug therapy (153) 153
risk (151) 151
risk factors (149) 149
coronary-heart-disease (147) 147
therapy (144) 144
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (142) 142
prevention (142) 142
c-reactive protein (141) 141
hyperlipidemias - drug therapy (141) 141
in vitro techniques (141) 141
statin therapy (136) 136
metabolism (134) 134
anticholesteremic agents - administration & dosage (133) 133
apoptosis (129) 129
cardiology (125) 125
cholesterol, hdl - blood (125) 125
rosuvastatin calcium (125) 125
pravastatin - pharmacology (124) 124
hematology (123) 123
medicine & public health (123) 123
rabbits (123) 123
rna, messenger - metabolism (123) 123
cardiovascular (121) 121
liver - metabolism (119) 119
cells (117) 117
heptanoic acids - chemistry (117) 117
prospective studies (117) 117
internal medicine (116) 116
cardiovascular disease (115) 115
apoptosis - drug effects (114) 114
medicine, research & experimental (114) 114
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2810) 2810
Chinese (42) 42
Japanese (14) 14
Russian (14) 14
Spanish (14) 14
German (6) 6
French (5) 5
Hungarian (4) 4
Polish (3) 3
Italian (2) 2
Portuguese (2) 2
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Applied Biochemistry and Biotechnology, ISSN 0273-2289, 05/2017, Volume 182, Issue 1, pp. 67 - 81
Docosapentaenoic acid/docosahexaenoic acid ratio (DPA/DHA ratio) in Schizochytrium was relatively stable. But ideally the ratio of DPA/DHA will vary according... 
Docosapentaenoic acid / docosahexaenoic acid ratio | Schizochytrium | Docosapentaenoic acid | Docosapentaenoic acid biosynthesis | Polyunsaturated fatty acid synthase | OXIDATION | Docosapentaenoic acid/docosahexaenoic acid ratio | BIOCHEMISTRY & MOLECULAR BIOLOGY | BETA | TRICHOPHYTON-RUBRUM | SYNTHASE INHIBITOR | OIL | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | DOCOSAHEXAENOIC ACID | BIOSYNTHESIS | FATTY-ACID | GROWTH | GENE-EXPRESSION | Propionates - pharmacology | Propionates - metabolism | Transcription, Genetic - drug effects | Heptanoic Acids - metabolism | Fatty Acid Synthases - metabolism | Caproates - pharmacology | Iodoacetamide - pharmacology | Stramenopiles - drug effects | Caprylates - pharmacology | Caprylates - metabolism | Fatty Acids, Unsaturated - biosynthesis | Stramenopiles - growth & development | Butyric Acid - metabolism | Pentanoic Acids - pharmacology | Butyric Acid - pharmacology | Pentanoic Acids - metabolism | Caproates - metabolism | Stramenopiles - genetics | Docosahexaenoic Acids - biosynthesis | Fatty Acid Synthases - genetics | Stramenopiles - enzymology | Heptanoic Acids - pharmacology | Fatty Acids - biosynthesis | Unsaturated fatty acids | Synthesis | Laws, regulations and rules | Analysis | Saturated fatty acids | Fatty acids | Omega-3 fatty acids | Fish oils | Transcription | Incubation | Polyunsaturated fatty acids | Propionic acid | Lipids | Oxidation | Docosahexaenoic acid | Octanoic acid | Butyric acid | Index Medicus
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 08/2004, Volume 24, Issue 8, pp. 1454 - 1459
OBJECTIVE—Neural apoptosis-regulated convertase (NARC)-1 is the newest member of the proprotein convertase family implicated in the cleavage of a variety of... 
HepG2 | QPCR | Primary hepatocytes | Cholesterol | SRE | CELLS | ELEMENT-BINDING PROTEIN-2 | primary hepatocytes | AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA | LOW-DENSITY-LIPOPROTEIN | NUCLEAR RECEPTOR LXR | TARGET GENES | PATHWAY | LIVER | cholesterol | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | Consensus Sequence | Lovastatin - pharmacology | Species Specificity | Humans | Regulatory Sequences, Nucleic Acid | Homeostasis | Lovastatin - analogs & derivatives | Hepatocytes - metabolism | Simvastatin - pharmacology | Promoter Regions, Genetic - genetics | Quinolines - pharmacology | RNA, Messenger - biosynthesis | Cell Line - drug effects | Base Sequence | Liver X Receptors | Serine Endopeptidases - genetics | Orphan Nuclear Receptors | Proprotein Convertases | Sp1 Transcription Factor - physiology | Hepatocytes - drug effects | Heptanoic Acids - pharmacology | Tretinoin - pharmacology | Mevalonic Acid - pharmacology | Cell Line - metabolism | DNA-Binding Proteins - physiology | Transcription Factors - physiology | Serine Endopeptidases - biosynthesis | Receptors, Cytoplasmic and Nuclear - drug effects | Rats | Hydroxymethylglutaryl CoA Reductases - physiology | Reverse Transcriptase Polymerase Chain Reaction | Hydroxycholesterols - pharmacology | Sequence Homology, Nucleic Acid | Gene Expression Regulation - drug effects | Mevalonic Acid - analogs & derivatives | Atorvastatin Calcium | Pyrroles - pharmacology | Sequence Alignment | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cholesterol - pharmacology | Mice | Pyridines - pharmacology | Cholesterol - biosynthesis | Sterol Regulatory Element Binding Protein 2 | Proprotein Convertase 9 | Index Medicus
Journal Article
Pharmacological Research, ISSN 1043-6618, 09/2011, Volume 64, Issue 3, pp. 180 - 186
Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in... 
Alzheimer disease | Pleiotropic functions | Statins | Statins as Janus molecules | OXIDATIVE STRESS | COA REDUCTASE INHIBITORS | CLINICAL-TRIAL COHORT | DRUG-INTERACTIONS | NITRIC-OXIDE SYNTHASE | MILD COGNITIVE IMPAIRMENT | CELL-DEATH | COENZYME Q | AMYLOID-BETA | PHARMACOLOGY & PHARMACY | AUTOIMMUNE-DISEASE | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Heptanoic Acids - therapeutic use | Humans | Heptanoic Acids - adverse effects | Neurodegenerative Diseases - drug therapy | Quinolines - pharmacology | Fluorobenzenes - pharmacology | Fatty Acids, Monounsaturated - therapeutic use | Fatty Acids, Monounsaturated - adverse effects | Pyrroles - adverse effects | Indoles - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Lovastatin - therapeutic use | Lovastatin - adverse effects | Alzheimer Disease - drug therapy | Rosuvastatin Calcium | Pyrimidines - pharmacology | Cholesterol - metabolism | Sulfonamides - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects | Alzheimer's disease | Neuroprotection | Neurotoxicity | Neurodegenerative diseases | statins | Dyslipidemia | Clinical trials | Age | Cholesterol | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2005, Volume 352, Issue 1, pp. 20 - 28
Statin therapy lowers not only low-density lipoprotein (LDL) cholesterol levels, but also levels of C-reactive protein (CRP), a marker of inflammation. This... 
MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | HEART-DISEASE | TREATMENT PANEL-III | INFLAMMATION | CARDIOVASCULAR-DISEASE | RISK | ACUTE CORONARY SYNDROMES | UNSTABLE ANGINA | PRAVASTATIN | PRIMARY PREVENTION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Male | Secondary Prevention | Coronary Disease - mortality | Incidence | C-Reactive Protein - metabolism | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | C-Reactive Protein - drug effects | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Coronary Disease - blood | Risk Factors | Proportional Hazards Models | Cholesterol, LDL - drug effects | Fluoroquinolones - therapeutic use | Biomarkers - blood | Atorvastatin Calcium | Coronary Disease - prevention & control | Pyrroles - pharmacology | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Infarction - prevention & control | Anticholesteremic Agents - pharmacology | Cardiovascular disease | Heart attacks | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Cardiovascular Research, ISSN 0008-6363, 05/2010, Volume 86, Issue 2, pp. 311 - 320
Journal Article
Journal of Experimental Medicine, ISSN 0022-1007, 10/2013, Volume 210, Issue 11, pp. 2205 - 2221
Journal Article
Journal Article
Clinical Science, ISSN 0143-5221, 08/2012, Volume 123, Issue 3, pp. 161 - 171
Journal Article
Circulation Research, ISSN 0009-7330, 02/2010, Volume 106, Issue 2, pp. 297 - 306
RATIONALE:The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, are important drugs used in the treatment and prevention of... 
Statins | Drug transporters | Myopathy | CARDIAC & CARDIOVASCULAR SYSTEMS | myopathy | EUROPEAN-AMERICANS | HEPATIC-UPTAKE | INDUCED MYOPATHY | P-GLYCOPROTEIN | drug transporters | LIPID-LOWERING DRUGS | statins | ORGANIC-ANIONS | PERIPHERAL VASCULAR DISEASE | COA-REDUCTASE INHIBITORS | RESISTANCE-ASSOCIATED PROTEIN-2 | HEALTHY-VOLUNTEERS | MULTIDRUG-RESISTANCE | HEMATOLOGY | Immunohistochemistry | Fluorobenzenes - pharmacokinetics | Heptanoic Acids - metabolism | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Immunoblotting | Muscle, Skeletal - metabolism | Gene Expression Profiling | Muscle, Skeletal - cytology | Organic Anion Transporters - metabolism | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Myoblasts - metabolism | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Myoblasts - cytology | Multidrug Resistance-Associated Proteins - genetics | Heptanoic Acids - pharmacology | Cell Survival - drug effects | Fluorobenzenes - metabolism | Pyrroles - metabolism | Cells, Cultured | Rosuvastatin Calcium | Pyrimidines - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - metabolism | Pyrimidines - pharmacokinetics | HeLa Cells | Multidrug Resistance-Associated Proteins - metabolism | Index Medicus
Journal Article